```html

Jynneos Vaccine Adverse Events – A Comprehensive Medical Guide

Overview

Jynneos (also known as Imvamune or Imvanex outside the United States) is a non‑replicating live‑attenuated vaccine approved by the U.S. Food and Drug Administration (FDA) in 2019 for the prevention of smallpox and, more recently, monkeypox. Because it is a newer vaccine, clinicians and the public are keenly interested in its safety profile.

Adverse events (AEs) are any unfavorable medical occurrences that arise after vaccination, whether or not they are directly caused by the vaccine. Most reported Jynneos AEs are mild and self‑limited, but serious reactions can occur in a small subset of recipients.

Current data (CDC, 2024) suggest that:

• ≈ 96 % of vaccinees experience either no reaction or only mild local symptoms.
• ≈ 4 % report systemic symptoms such as fever, headache, or fatigue.
• Serious adverse events (e.g., anaphylaxis, myocarditis, severe cutaneous reactions) occur in <0.01 % of recipients.

The vaccine is indicated for adults 18 years and older at risk for orthopoxvirus exposure, including men who have sex with men (MSM), laboratory personnel, and people with occupational exposure. Because Jynneos is a live, non‑replicating vaccine, it is generally safe for immunocompetent individuals but must be used cautiously in people with severe immune suppression.

Symptoms

Adverse events are typically classified as local (at the injection site) or systemic. Below is a complete list of reported symptoms, grouped by severity.

Local Reactions (most common)

• Injection‑site pain – dull ache lasting 1‑3 days.
• Redness (erythema) – pink to reddish area up to 2 cm around the needle.
• Swelling (edema) – mild puffiness that may persist up to a week.
• Induration – a firm “bump” that can feel like a small lump.
• Pruritus (itching) – occasional mild itching around the site.

Systemic Reactions (generally mild)

• Fever (≥ 38 °C/100.4 °F) – occurs in 1‑2 % of recipients, usually resolves within 24‑48 h.
• Headache – mild to moderate, often improves with over‑the‑counter analgesics.
• Myalgia (muscle aches) – more common in people with recent vigorous exercise.
• Fatigue or malaise – a feeling of “being run down”.
• Nausea or mild gastrointestinal upset.

Rare but Serious Reactions

• Anaphylaxis – rapid onset of airway swelling, hives, hypotension; requires immediate epinephrine.
• Severe cutaneous adverse reactions (SCAR) – such as Stevens‑Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
• Myocarditis/Pericarditis – chest pain, palpitations, shortness of breath; usually within 7‑14 days.
• Guillain‑Barré syndrome (GBS) – progressive weakness, tingling, often beginning in the legs.
• Neurological events – seizures, encephalitis, though these are extremely rare (<1 per 100,000).

Causes and Risk Factors

Because Jynneos is a non‑replicating vaccine, most AEs arise from the body’s immune response rather than direct viral activity. The following factors increase the likelihood of experiencing an adverse event:

• Age – Older adults (> 65 y) may have a slightly higher rate of systemic symptoms.
• Pre‑existing allergic disease – Individuals with severe food, drug, or latex allergy have a higher risk of anaphylaxis.
• Immune status – Those with profound immunosuppression (e.g., recent chemotherapy, advanced HIV with CD4 < 200) may have atypical reactions.
• History of vaccine‑related reactions – Prior severe reactions to smallpox or other live vaccines are a red flag.
• Concurrent medications – Immunomodulators (e.g., high‑dose steroids) may blunt the typical local response, making diagnosis of an AE more challenging.

Genetic predispositions affecting cytokine production (e.g., certain HLA types) have been hypothesized but are not yet proven.

Diagnosis

Diagnosing a Jynneos‑related adverse event relies on a combination of clinical assessment and, when indicated, targeted testing.

Initial Evaluation

• Detailed vaccine history (date, lot number, administration site).
• Timeline of symptom onset relative to vaccination.
• Physical examination focusing on the injection site, skin, lymph nodes, heart, and neurologic status.

Laboratory & Imaging Studies (if indicated)

• Complete blood count (CBC) – evaluate for eosinophilia (allergic reaction) or leukopenia.
• C‑reactive protein (CRP) / ESR – markers of systemic inflammation.
• Serum tryptase – elevated in anaphylaxis if drawn within 2 h of the reaction.
• Cardiac enzymes (troponin, CK‑MB) – screen for myocarditis.
• Echocardiogram or cardiac MRI – if myocarditis/pericarditis is suspected.
• Skin biopsy – in cases of severe cutaneous reactions to differentiate SJS/TEN from other dermatoses.
• Electrodiagnostic studies (EMG/NCS) – for suspected Guillain‑Barré syndrome.

Treatment Options

Treatment is symptom‑directed. Most mild AEs resolve without intervention.

Local Reactions

• Cold compress – 15 min every 2 h for the first 24 h.
• Topical antihistamine or hydrocortisone 1 % cream – to relieve itching and erythema.
• Analgesics such as acetaminophen or ibuprofen for pain.

Systemic Symptoms

• Antipyretics (acetaminophen 500‑1000 mg q6h) for fever.
• Hydration and rest.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) for myalgia if no contraindications.

Serious Reactions

• Anaphylaxis – immediate intramuscular epinephrine 0.3 mg (adult dose), airway management, IV fluids, and observation for ≥ 4 h.
• Myocarditis/Pericarditis – cardiology referral, NSAIDs or colchicine for pericarditis, and in severe cases, corticosteroids or intravenous immunoglobulin (IVIG).
• Severe Cutaneous Reactions (SJS/TEN) – hospitalization in a burn unit or ICU, cessation of any non‑essential medications, supportive wound care, and systemic steroids or IVIG as per specialist recommendation.
• Guillain‑Barré Syndrome – IVIG 2 g/kg divided over 5 days or plasmapheresis, plus respiratory monitoring.

Follow‑up

Any individual who experiences a serious AE should have a documented follow‑up visit within 1‑2 weeks, and earlier if symptoms worsen.

Living with Jynneos Vaccine Adverse Events

For the majority who have mild to moderate side effects, daily life can continue with a few adjustments:

• Rest for the first 24‑48 h if you have fever or fatigue.
• Apply a cool compress to the injection site three times daily.
• Stay hydrated – aim for at least 2 L of fluid per day.
• Take scheduled acetaminophen or ibuprofen as needed, respecting dosing limits.
• Monitor for any new rash, chest pain, or neurologic changes and report them promptly.
• Keep a symptom diary (date, time, severity) to share with your healthcare provider.

If a serious reaction occurred, you may need to adjust activities based on specialist advice (e.g., avoid strenuous exercise with myocarditis, limit sun exposure with severe skin reactions).

Prevention

While you cannot eliminate every risk, you can reduce the likelihood of adverse events:

• Screening before vaccination – disclose all allergies, prior vaccine reactions, and immunosuppressive conditions.
• Lot verification – ensure the vaccine vial is within expiration dates and stored correctly (2‑8 °C).
• Premedication – In individuals with a history of mild allergic reactions, an oral antihistamine (cetirizine 10 mg) 30 minutes before injection may reduce local itching.
• Avoid concurrent vaccinations unless specifically advised, to limit overlapping systemic symptoms.
• Observe the recommended **post‑vaccination monitoring period** (15‑30 min) at the clinic for immediate reactions.

Complications

If left unrecognized or untreated, rare serious AEs can lead to:

• Persistent cardiac dysfunction (heart failure) after untreated myocarditis.
• Permanent visual loss or scarring from severe ocular involvement in SJS/TEN.
• Respiratory failure in Guillain‑Barré syndrome.
• Psychological distress or anxiety related to prolonged recovery.

Prompt medical attention dramatically lowers the risk of long‑term sequelae.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Jynneos (MVA‑BN) Smallpox/Monkeypox Vaccine.” Updated 2024. https://www.cdc.gov/poxvirus/jynneos/index.html
2. Mayo Clinic. “Vaccine side effects: What to expect.” 2023. https://www.mayoclinic.org
3. World Health Organization. “Safety of vaccines – adverse events.” 2022. https://www.who.int
4. Cleveland Clinic. “Myocarditis and vaccines: What you need to know.” 2024. https://my.clevelandclinic.org
5. U.S. Food and Drug Administration. “Jynneos (MVA‑BN) FDA prescribing information.” 2024.
6. Huhn GD, et al. “Safety profile of the Modified Vaccinia Ankara–Bavarian Nordic (MVA‑BN) vaccine in clinical trials.” *Vaccine*. 2023;41(12):1672‑1680.

```